Literature DB >> 22301440

Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Richard G Moore1, Michael Craig Miller, Elizabeth E Eklund, Karen H Lu, Robert C Bast, Geralyn Lambert-Messerlian.   

Abstract

OBJECTIVE: The purpose of this study was to establish normal ranges for human epididymis protein 4 (HE4) serum levels in healthy women. STUDY
DESIGN: HE4 levels were measured in healthy women and analyzed by age, menopausal status, and pregnancy status. Upper 95th percentiles were determined for normal ranges.
RESULTS: Serum samples from 1101 healthy women and 67 pregnant women were analyzed. Above the age of 40 years significant elevations in HE4 concentrations emerged with advancing age. The upper 95th percentile for HE4 levels was 89 pmol/L for premenopausal women, 128 pmol/L for postmenopausal women, and 115 pmol/L for all women. There was a significant difference in the median serum HE4 levels in premenopausal women (46.6 pmol/L) compared with postmenopausal women (57.6 pmol/L; P < .001). In pregnant women, median HE4 concentrations were significantly lower than their premenopausal counterparts (P < .001).
CONCLUSION: HE4 serum concentrations vary significantly on the basis of age. These variations must be considered when the upper limit of normal for HE4 is determined.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22301440      PMCID: PMC3987114          DOI: 10.1016/j.ajog.2011.12.028

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  27 in total

1.  Benign conditions associated with raised serum CA-125 concentration.

Authors:  P Buamah
Journal:  J Surg Oncol       Date:  2000-12       Impact factor: 3.454

2.  Factors influencing serum CA125II levels in healthy postmenopausal women.

Authors:  D K Pauler; U Menon; M McIntosh; H L Symecko; S J Skates; I J Jacobs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

3.  Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.

Authors:  Richard G Moore; M Craig Miller; Paul Disilvestro; Lisa M Landrum; Walter Gajewski; John J Ball; Steven J Skates
Journal:  Obstet Gynecol       Date:  2011-08       Impact factor: 7.661

4.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Authors:  Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

5.  Characterization of CA 125 synthesized by the human epithelial amnion WISH cell line.

Authors:  J L Fendrick; K A Staley; M K Gee; S R McDougald; J G Quirk; T J O'Brien
Journal:  Tumour Biol       Date:  1993

6.  Increased serum CA 125 levels during the first trimester of pregnancy.

Authors:  K Seki; Y Kikuchi; T Uesato; K Kato
Journal:  Acta Obstet Gynecol Scand       Date:  1986       Impact factor: 3.636

7.  CA 125 in the serum and tissue of patients with gynecological disease.

Authors:  L C Fuith; G Daxenbichler; O Dapunt
Journal:  Arch Gynecol Obstet       Date:  1987       Impact factor: 2.344

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  CA125 antigen levels in obstetric and gynecologic patients.

Authors:  J M Niloff; R C Knapp; E Schaetzl; C Reynolds; R C Bast
Journal:  Obstet Gynecol       Date:  1984-11       Impact factor: 7.661

10.  Serum CA 125 concentrations in patients with benign ovarian tumours.

Authors:  P K Buamah; A W Skillen
Journal:  J Surg Oncol       Date:  1994-06       Impact factor: 3.454

View more
  47 in total

1.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

2.  Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.

Authors:  Q-L Li; C-J Wang; P Qi; Y-X Zhang
Journal:  Clin Transl Oncol       Date:  2017-04-25       Impact factor: 3.405

Review 3.  Management of gynecological cancers during pregnancy.

Authors:  Sileny N Han; Magali Verheecke; Tineke Vandenbroucke; Mina Mhallem Gziri; Kristel Van Calsteren; Frédéric Amant
Journal:  Curr Oncol Rep       Date:  2014-12       Impact factor: 5.075

Review 4.  The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Authors:  Archana R Simmons; Keith Baggerly; Robert C Bast
Journal:  Oncology (Williston Park)       Date:  2013-06       Impact factor: 2.990

5.  Comparison of HE4 and CA125 levels in women with benign gynecologic disorders : Does age or menopausal status matter?

Authors:  Ratko Delić; Mario Štefanović; Štefka Krivec; Vladimir Weber; Jakob Koren
Journal:  Wien Klin Wochenschr       Date:  2016-10-17       Impact factor: 1.704

6.  Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Authors:  Nicole Urban; Jason Thorpe; Beth Y Karlan; Martin W McIntosh; Melanie R Palomares; Mary B Daly; Pamela Paley; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-09-07       Impact factor: 4.254

Review 7.  The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.

Authors:  L-T Jia; Y-C Zhang; J Li; Y Tian; J-F Li
Journal:  Clin Transl Oncol       Date:  2015-07-29       Impact factor: 3.405

8.  Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression.

Authors:  Shin-ichi Yamashita; Keita Tokuishi; Toshihiko Moroga; Satoshi Yamamoto; Kazuyuki Ohbo; So Miyahara; Yasuhiro Yoshida; Jun Yanagisawa; Daisuke Hamatake; Masafumi Hiratsuka; Yasuteru Yoshinaga; Takeshi Shiraishi; Akinori Iwasaki; Katsunobu Kawahara
Journal:  Tumour Biol       Date:  2012-09-22

9.  The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.

Authors:  Qiong Zhang; Cong-Rong Wang; Juan-Ping Yu; Qiang Ma; Wei-Wen Xu
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

10.  Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass.

Authors:  Elizabeth Lokich; Marguerite Palisoul; Nicole Romano; M Craig Miller; Katina Robison; Ashley Stuckey; Paul DiSilvestro; Cara Mathews; C O Granai; Geralyn Lambert-Messerlian; Richard G Moore
Journal:  Gynecol Oncol       Date:  2015-09-11       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.